Record ID 32016000953
Authors' recommendations: Non-small cell lung cancer (NSCLC) encompasses squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In the United States in 2015, it is estimated that NSCLC was diagnosed in more than 221,000 individuals and resulted in more than 158,000 deaths. More than 80% of lung cancer patients have NSCLC. The VeriStrat test relies on matrix-assisted laser desorption/deionization timeof-flight (MALDI-TOF) mass spectrometry to analyze pretreatment serum from NSCLC patients who are candidates for EGFR TKI therapy. This test has been developed with the goal of identifying patients most likely to benefit from EGFR TKI therapy. The VeriStrat test is considered a proteomic profiling assay, or a test that identifies specific patterns of protein expression in cells, plasma, or tissue. This report focuses on the use of the VeriStrat test as a prognostic tool and to predict response to EGFR TKIs in NSCLC.
Project Status: Completed
Year Published: 2016
URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=13553
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
- Lung Neoplasms
- Carcinoma, Large Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: 2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.